Common questions about Trelstar (FAQ)
Q: How quickly does Trelstar start working after the first injection?
A: Trelstar begins to act on the body immediately upon injection, but its main goal is to reduce testosterone levels. According to official product information, a temporary, initial surge in the hormone occurs, followed by a decline to very low, or castrate levels, typically reached within four weeks of the first dose. This achievement of low testosterone levels indicates that the goal of hormonal suppression has been met.
Q: Is Trelstar treatment given as a single shot or multiple shots?
A: Trelstar is administered by a healthcare professional as a single intramuscular injection into the buttock. However, because it is designed to be an extended-release depot, the treatment regimen involves repeated injections based on the prescribed schedule. Depending on the strength used, the subsequent injection will be given every 4, 12, or 24 weeks to maintain consistent hormonal suppression.
Q: Do women or children ever receive Trelstar?
A: Official regulatory documents indicate that Trelstar is only indicated for use in adult males with advanced prostate cancer. The drug is contraindicated (formally excluded) for use in women who are pregnant or nursing (breastfeeding). Furthermore, the safety and effectiveness of Trelstar have not been established in children.
Q: What are the differences between Trelstar LA and other formulations?
A: Trelstar comes in different dosage strengths (e.g., 3.75 mg, 11.25 mg, and 22.5 mg), which are selected based on the required dosing interval. These strengths are not interchangeable, as each is specifically formulated to provide a slow, continuous release over different time periods, such as every 4, 12, or 24 weeks.
Q: Why do some people need to take another drug at the beginning of Trelstar therapy?
A: During the first few weeks of Trelstar treatment, a transient increase in testosterone can occur before the hormone levels drop. This temporary surge can cause a worsening of symptoms, known as a tumor flare. Healthcare providers may manage this with an additional medication, such as an anti-androgen, during this initial period.
Q: Can Trelstar cause muscle weakness or joint pain?
A: Official reports from clinical trials indicate that arthralgia (joint pain) is a commonly reported adverse reaction. While skeletal pain has also been reported, muscle weakness is not explicitly listed as a common side effect in the primary drug safety profile.
Q: Does Trelstar cause weight gain?
A: The official safety profile reports some instances of unusual weight gain or loss. Weight changes may be linked to other effects of the medication, such as edema (fluid retention), which has also been reported in clinical experience.
Q: Can Trelstar affect sleep patterns?
A: Official reports of adverse reactions from clinical trials have included instances of insomnia, or trouble sleeping. This means that changes to sleep patterns are a possible effect of the medication.
Q: Does Trelstar affect a person's mood or cause depression?
A: Postmarketing reports have included instances of mood or mental changes in patients using this medication. These changes may include feelings of anxiety, agitation, irritability, and even delusions.
Q: Are there any documented effects of Trelstar on vision or eyes?
A: Adverse reactions reported in official sources have included conjunctivitis and eye pain. If serious eye symptoms such as sudden vision loss or blurred vision occur, official guidance states that these are medically serious symptoms that should be reported to a healthcare professional immediately.
Q: Is Trelstar considered palliative care or curative treatment?
A: Trelstar is formally indicated for the palliative treatment of advanced prostate cancer. This means the therapy is designed to manage and reduce symptoms to improve the quality of life, but it is not intended to cure the underlying condition.
Q: What are the potential effects of Trelstar on cholesterol levels?
A: The use of this class of drugs, known as Androgen Deprivation Therapy, may lead to metabolic changes. Official warnings indicate that monitoring for the development of hyperlipidemia (high levels of fat or cholesterol in the blood) is part of the treatment management.
Q: Is it typical for Trelstar to be used alongside radiation therapy?
A: While the primary regulatory label focuses on advanced prostate cancer, clinical guidelines recommend Trelstar as adjuvant therapy in some cases. This means it may be administered alongside or following other treatments, such as radiation therapy, in certain patient populations.
Q: Can Trelstar be used in patients with a history of seizures?
A: Convulsions have been reported in patients treated with this drug class. Official prescribing information notes that caution is advised for patients with risk factors for seizures, or those taking co-medications that increase seizure risk.
Q: Is it normal for the injection site to be sore after Trelstar?
A: Injection site pain is a reported adverse reaction in clinical trial experience. Because Trelstar is administered as an intramuscular depot injection, some soreness or discomfort at the injection site may be expected.
Q: What patient monitoring or lab tests are usually required during Trelstar treatment?
A: Healthcare providers will typically monitor certain levels during treatment. This monitoring usually includes measuring serum testosterone levels to ensure castrate levels are being maintained. They may also monitor for changes in metabolism, such as the potential development of hyperglycemia or diabetes, by tracking blood glucose levels.
